Bioequivalence Study of Lamotrigine Tablets 25 mg (2 x 25 mg Tablets) Under Fasting Condition

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
IPCA Laboratories Ltd.
ClinicalTrials.gov Identifier:
NCT01618799
First received: June 11, 2012
Last updated: NA
Last verified: June 2012
History: No changes posted
  Purpose

This is an open Label, randomized, two-period, two-treatment, two-sequence, crossover, balanced, single dose pivotal study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding Reference Product under fasting condition in healthy adult human subjects.


Condition Intervention Phase
Fasting State
Drug: Lamotrigine Tablets 25 mg
Drug: Lamotrigine
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Crossover, Balanced, Single Dose Oral Bioequivalence Study of Lamotrigine Tablets 25 mg (2 × 25 mg Tablets) and 'LAMICTAL®' (Lamotrigine) Tablets 25 mg (2 × 25 mg Tablets) in Healthy Adult Human Subjects Under Fasting Conditions.

Resource links provided by NLM:


Further study details as provided by IPCA Laboratories Ltd.:

Primary Outcome Measures:
  • Bioequivalence is based on Cmax and AUC parameters. [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Area Under Curve (AUC)and Cmax Sampling Hours: Pre-dose and at 00.25, 00.5, 00.75, 01.00, 01.25, 01.50, 01.75, 02.00, 02.25, 02.50, 03.00, 03.25, 03.50, 04.00, 04.25, 05.00, 06.00, 08.00, 10.00, 12.00, 18.00, 24.00, 36.00, 48.00 and 72.00 hours post-dose.


Enrollment: 28
Study Start Date: March 2012
Study Completion Date: May 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: LAMICTAL®
Lamictal® (Lamotrigine) Tablets 25 mg of GlaxoSmithkline, USA
Drug: Lamotrigine
2 x 25 mg tablet once a day
Other Name: LAMICTAL®
Experimental: Lamotrigine Tablets 25 mg
Lamotrigine Tablets 25 mg of M/s Ipca Laboratories Limited, India
Drug: Lamotrigine Tablets 25 mg
2 x 25 mg tablet once a day
Other Name: Test Product

Detailed Description:

Objective of this pivotal study was to assess the bioequivalence between Test Product: Lamotrigine Tablets 25 mg (2 x 25 mg)of M/s Ipca Laboratories Limited, India and the corresponding Reference Product: LAMICTAL® (Lamotrigine) Tablets 25 mg (2 x 25 mg) of GlaxoSmithkline, USA, under fasting condition in healthy adult human subjects in a randomized crossover study.

The study was conducted with 28 healthy adult subjects. In each study period, a single 2 X 25 mg dose of either test or reference was administered to the subjects as per the randomization schedule in each study period with about 240 mL of water at ambient temperature in sitting position.

The duration of the clinical phase was approximately 26 days including washout period of at least 21 days between administrations of study drug in each study period.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Age: 18 to 45 years old, both inclusive.
  2. Sex: Males and/or non-pregnant, non-lactating females.

    A. Females of childbearing potential must have a negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test performed within 21 days prior to initiation of the study & prior to check-in of each period. They must be using an acceptable form of contraception.

    B. Acceptable forms of contraception include the following:

    i. Intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study period, or

    ii. Barrier methods containing or used in conjunction with a spermicidal agent, or

    iii. Surgical sterilization or

    iv. Practicing sexual abstinence throughout the course of the study.

    C. Females will not be considered of childbearing potential if one one of the following is reported and documented on the medical history:

    i. Postmenopausal with spontaneous amenorrhea for at least one year, or

    ii. Bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months, or

    iii. Total hysterectomy and an absence of bleeding for at least 3 months.

  3. BMI: 18.5 to 24.9 weight in Kg / (height in meter)2 both inclusive; BMI value should be rounded off to one significant digit after decimal point (e.g. 24.94 rounds down to 24.9. while 18.45 rounds up to 18.5).
  4. Able to communicate effectively with study personnel and willingness to follow the protocol requirements as evidenced by written informed consent.
  5. Able to give written informed consent to participate in the study.
  6. All volunteers must be judged by the principal or co-investigator or physician as normal and healthy during pre-study safety assessment performed within 21 days of the first dose of study medication which will include:

    1. A physical examination with no clinically significant finding.
    2. Results within normal limits or clinically non-significant for the tests mentioned in list of Laboratory Parameters:

      • Additional tests and/or examinations may be performed, if necessary, based on Principal Investigator discretion.
      • All results will be assessed against the laboratory normal ranges current at the time of testing and a copy of the normal ranges used will be included in the study documentation.

Exclusion Criteria:

  1. History of allergic responses to Lamotrigine or other related drugs, or any of its formulation ingredients.
  2. Have significant diseases or clinically significant abnormal findings during screening, [medical history, physical examination, laboratory evaluations, ECG, chest X-ray recording, obstetrics and gynecological history and examination along with PAP smear (for female volunteers) & transvaginal ultrasonography (for female volunteers)].
  3. Any disease or condition which might compromise the haemopoeitic gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system, diabetes, psychosis or any other body system.
  4. History or presence of bronchial asthma.
  5. Use of any hormone replacement therapy within 3 months prior to study medication dosing.
  6. A depot injection or implant of any drug within 3 months prior to administration of study medication.
  7. Use of enzyme-modifying drugs within 30 days prior to receiving the first dose of study medication.
  8. History or evidence of drug dependence or of alcoholism or of moderate alcohol use.
  9. Smokers who smoke 10 or more cigarettes per day or 20 or more biddies per day or those who cannot refrain from smoking during the study period.
  10. History of difficulty with donating blood or difficulty in accessibility of veins.
  11. History of allergic response to heparin.
  12. A positive hepatitis screen (includes subtypes B & C).
  13. A positive test result for HIV antibody and / or syphilis (RPR/VDRL).
  14. Volunteers who have donated blood (1 unit or 450 ml) within 90 days prior to the initial dose of the study drug or have blood loss, excluding volume drawn at screening for this study drug.
  15. History of difficulty in swallowing, or of any gastrointestinal disease which could affect drug absorption.
  16. Intolerance to venipuncture.
  17. Any food allergy, intolerance, restriction or special diet that, in the opinion of the Principal Investigator, could contraindicate the volunteer's participation in this study.
  18. Volunteers who have received a known investigational drug within five elimination half life of the administered drug prior to the initial dose of study drug or who have participated in a clinical drug study or bioequivalence study within 90 days prior to initial dose of study drug, whichever is greater.
  19. Found positive in urine test for drugs of abuse done before check-in of period I.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01618799

Locations
India
Cliantha Research Limited
Ahmedabad, Gujarat, India
Sponsors and Collaborators
IPCA Laboratories Ltd.
Investigators
Principal Investigator: Dr. Manish Singhal, MBBS Cliantha Research Limited
  More Information

No publications provided

Responsible Party: IPCA Laboratories Ltd.
ClinicalTrials.gov Identifier: NCT01618799     History of Changes
Other Study ID Numbers: Ipca/BA/1264033
Study First Received: June 11, 2012
Last Updated: June 11, 2012
Health Authority: India: Ministry of Health
United States: Institutional Review Board

Additional relevant MeSH terms:
Anticonvulsants
Lamotrigine
Calcium Channel Blockers
Cardiovascular Agents
Central Nervous System Agents
Excitatory Amino Acid Agents
Excitatory Amino Acid Antagonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sodium Channel Blockers
Therapeutic Uses
Voltage-Gated Sodium Channel Blockers

ClinicalTrials.gov processed this record on October 23, 2014